These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10739910)

  • 1. An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease.
    Munshi S; Chen Z; Yan Y; Li Y; Olsen DB; Schock HB; Galvin BB; Dorsey B; Kuo LC
    Acta Crystallogr D Biol Crystallogr; 2000 Apr; 56(Pt 4):381-8. PubMed ID: 10739910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.
    Chen Z; Li Y; Schock HB; Hall D; Chen E; Kuo LC
    J Biol Chem; 1995 Sep; 270(37):21433-6. PubMed ID: 7665551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
    Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
    FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
    Todd MJ; Luque I; Velázquez-Campoy A; Freire E
    Biochemistry; 2000 Oct; 39(39):11876-83. PubMed ID: 11009599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational flexibility in the flap domains of ligand-free HIV protease.
    Heaslet H; Rosenfeld R; Giffin M; Lin YC; Tam K; Torbett BE; Elder JH; McRee DE; Stout CD
    Acta Crystallogr D Biol Crystallogr; 2007 Aug; 63(Pt 8):866-75. PubMed ID: 17642513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.
    Tie Y; Kovalevsky AY; Boross P; Wang YF; Ghosh AK; Tozser J; Harrison RW; Weber IT
    Proteins; 2007 Apr; 67(1):232-42. PubMed ID: 17243183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
    Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
    J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease.
    Rick SW; Topol IA; Erickson JW; Burt SK
    Protein Sci; 1998 Aug; 7(8):1750-6. PubMed ID: 10082371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
    Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
    Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.
    Chen X; Weber IT; Harrison RW
    J Mol Model; 2004 Dec; 10(5-6):373-81. PubMed ID: 15597206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.
    King NM; Melnick L; Prabu-Jeyabalan M; Nalivaika EA; Yang SS; Gao Y; Nie X; Zepp C; Heefner DL; Schiffer CA
    Protein Sci; 2002 Feb; 11(2):418-29. PubMed ID: 11790852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
    Lepsík M; Kríz Z; Havlas Z
    Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
    Rano TA; Cheng Y; Huening TT; Zhang F; Schleif WA; Gabryelski L; Olsen DB; Kuo LC; Lin JH; Xu X; Olah TV; McLoughlin DA; King R; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1527-30. PubMed ID: 10915042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
    Clemente JC; Moose RE; Hemrajani R; Whitford LR; Govindasamy L; Reutzel R; McKenna R; Agbandje-McKenna M; Goodenow MM; Dunn BM
    Biochemistry; 2004 Sep; 43(38):12141-51. PubMed ID: 15379553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.
    Goldfarb NE; Ohanessian M; Biswas S; McGee TD; Mahon BP; Ostrov DA; Garcia J; Tang Y; McKenna R; Roitberg A; Dunn BM
    Biochemistry; 2015 Jan; 54(2):422-33. PubMed ID: 25513833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.